Full Text
Cost Utility Analysis (CUA) of Nivolumab Compared To Everolimus for The Treatment of Metastatic Renal Cell Carcinoma (RCC) in Australia

Abstract

Authors

D Liew N Patten M Tan H Kim

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×